Turning Point Brands walked into this earnings report with a premium P/E of 35.9x and a stock that had slipped over the past month. The market shrugged that off and marked the shares up about 2.6% today. The reason sits squarely in nicotine pouches. Modern Oral revenue jumped to nearly half of total net sales in the quarter, while group revenue reached about US$143 million.

Investors now face a clear trade off. The growth engine looks powerful, yet adjusted EBITDA fell sharply as Turning Point Brands poured cash into marketing, sales and regulatory work. The rest of this report examines that tension in more detail.

Is Turning Point Brands really priced for growth at a 35.9x P/E while margins and earnings forecasts soften, or has the market pushed too far? Compare that story with our valuation analysis for Turning Point Brands.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$142.96m vs. US$116.63m (up about 23%)
• Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): US$3.60m vs. US$14.48m (down sharply)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.18 vs. US$0.81 (down sharply)
• Adjusted EBITDA Margin (Q2 2026): 11% on adjusted EBITDA of US$15m (compressed due to higher sales and marketing spending)

Prefer clean charts instead of another wall of earnings figures and commentary? Get a full visual breakdown of Turning Point Brands, with a focus on its valuation picture, in the company report for Turning Point Brands.

Turning Point Brands’ Growth Story Gets a Real Test

Bulls argue that Turning Point Brands is becoming a nicotine pouch growth leader that can eventually support stronger earnings through scale, better manufacturing and category premiumization. Q2 gives real proof on the top line. Modern Oral net sales reached US$68m and now account for 48% of company revenue, up from roughly a quarter a year ago. Stoker’s segment revenue rose to US$108m and management lifted Modern Oral gross and net sales guidance for 2026 while keeping full year EBITDA guidance unchanged. That suggests confidence that higher Modern Oral volume and future U.S. manufacturing can offset heavier marketing and PMTA, or Premarket Tobacco Product Application, spend over time. The company also generated US$26m of free cash flow and still chose to raise US$60m of equity to fund Modern Oral. The growth engine is clearly working on revenue, but it is still being paid for in cash and earnings.

Margins, Dilution And Execution Risks Still Bite

Bears focus on the risk that Turning Point Brands overpays for growth and never fully rebuilds profitability. Q2 margins give them support. Adjusted EBITDA fell to US$15m with an 11% margin even as revenue rose to US$143m. Net income excluding extras dropped to US$3.6m and basic EPS fell to US$0.18 compared with US$0.81 a year earlier. SG&A jumped to US$77m, reflecting heavier marketing and sales spending that has not yet translated into margin repair. Equity issuance of US$60m and prior share count growth add to the concern that Modern Oral expansion dilutes existing holders while profits stall. Zig Zag net sales of US$35m were soft and Stoker’s heritage tobacco slipped slightly, which limits help from legacy cash generators. Maintaining full year EBITDA guidance while raising Modern Oral revenue targets shows discipline, but also highlights how tight the margin equation has become.

Compare Turning Point Brands’ internal growth story on Modern Oral and EBITDA guidance with how the street is reacting to the post earnings move in NYSE:TPB. See the consensus price target analysis for Turning Point Brands

Take Control Of Your Next Move

If the mix of Modern Oral growth and margin pressure at Turning Point Brands has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. Once you are invested, use the Portfolio Command Center to cut through day to day noise and focus on essential updates that matter for your holdings. For longer term context, tap into the Community to see how other investors are thinking about risks like dilution and profitability versus growth. By spotting potential catalysts and warning signs early, you give yourself a better chance of staying ahead of the market rather than reacting to it.

Seeking Alternatives Beyond Turning Point Brands?

Fresh ideas move fast. Some stocks are building breakout momentum while they are still under the radar for now. Scan these curated shortlists before the best entries get caught. Act now.

• Spot income workhorses that aim to keep paying even when headlines turn noisy by reviewing the 7 dividend fortresses that could support a steadier cash flow profile.
• Zero in on financially solid operators that are not flying across every headline yet by checking the curated list of solid balance sheet and fundamentals stocks (49 results) before the crowd starts chasing them.
• Hunt for future leaders hiding in plain sight by scanning the hand picked 18 high quality undiscovered gems while the story still feels early for long term investors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.